Relief Therapeutics Shareholders Approve Business Combination with NeuroX Nov 14, 2025 12:40PM
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 Oct 29, 2025 02:20AM
Relief Therapeutics Publishes 2025 Half-Year Report Aug 14, 2025 01:20AM
Relief Therapeutics Advances Publication of 2025 Half-Year Report Aug 11, 2025 01:20AM
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze Jul 29, 2025 01:20AM


Jun 20, 2025 01:20AM Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Jun 12, 2025 06:17AM Relief Therapeutics Announces Results of Annual General Meeting
May 22, 2025 01:20AM Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
May 15, 2025 01:20AM Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Apr 10, 2025 01:20AM Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Mar 6, 2025 01:15AM Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Feb 11, 2025 01:20AM Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Jan 22, 2025 01:20AM Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Dec 27, 2024 01:20AM Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Dec 16, 2024 01:20AM Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Dec 13, 2024 05:25PM Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Nov 11, 2024 01:20AM Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Nov 4, 2024 01:20AM Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Oct 29, 2024 02:20AM Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Oct 25, 2024 01:20AM Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Oct 21, 2024 01:20AM Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Oct 4, 2024 01:20AM Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Sep 23, 2024 01:20AM Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Sep 18, 2024 01:20AM Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Sep 2, 2024 01:20AM Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Aug 30, 2024 01:25AM Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Aug 5, 2024 01:20AM Relief Therapeutics Secures up to $11 Million from Royalty Sales
Jun 27, 2024 07:00AM RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting